Summary

The 7 major Fuchs dystrophy markets reached a value of US$ 148.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 292.9 Million by 2034, exhibiting a growth rate (CAGR) of 6.38% during 2024-2034.

The Fuchs dystrophy market has been comprehensively analyzed in IMARC's new report titled "Fuchs Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fuchs dystrophy is a progressive eye disease that damages the cornea, which is the transparent, dome-shaped surface that covers the front of the eye. It is a hereditary condition that affects women more frequently than men. The main symptom of the ailment is gradual loss of vision, which typically begins in the morning and improves throughout the day. As the condition progresses, patients may experience increased sensitivity to light, blurred vision, and difficulty seeing at night. In advanced cases, fluid may accumulate in the cornea, causing swelling and distortion of vision. Fuchs dystrophy can be diagnosed through a comprehensive eye exam performed by an ophthalmologist. During the exam, the doctor will evaluate the patient's vision and check for signs of corneal swelling or thickening. They also use a special microscope called a slit lamp to examine the cornea in detail and assess the health of the cells that line its surface. In addition to this, the doctor may perform specular microscopy, which uses a special camera to create a high-resolution image of the cornea's inner layer. This can help to detect changes in the cells that may indicate the presence of Fuchs dystrophy. In a few cases, genetic testing is also recommended to confirm the diagnosis.

The increasing cases of genetic mutations that affect the production of proteins in the cornea, which further lead to progressive thinning and clouding of the cornea, are primarily driving the Fuchs dystrophy market. In addition to this, the inflating adoption of steroids and nonsteroidal anti-inflammatory drugs to reduce inflammation and swelling in the cornea, thereby improving vision and easing discomfort, is also bolstering the market growth. Moreover, the rising application of phototherapeutic keratectomy (PTK) to remove excess corneal tissue and smooth out the surface of the cornea is acting as another significant growth-inducing factor. Apart from this, the escalating demand for bandage contact lenses, since they protect the cornea from further damage by providing a smooth surface for the eyelid to glide over, is creating a positive outlook for the market. They also aid in alleviating swelling and improving vision by drawing excess fluid from the cornea. Additionally, the emerging popularity of Descemet membrane endothelial keratoplasty on account of its several associated benefits, such as reduced risk of rejection, lowered likelihood of astigmatism, minimal impact on the cornea, faster recovery time, etc., is expected to drive the Fuchs dystrophy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Fuchs dystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Fuchs dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Fuchs dystrophy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Fuchs dystrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Fuchs dystrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Fuchs dystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Fuchs dystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Fuchs dystrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Fuchs dystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Fuchs dystrophy across the seven major markets?
What is the number of prevalent cases (2018-2034) of Fuchs dystrophy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Fuchs dystrophy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Fuchs dystrophy across the seven major markets?
What is the size of the Fuchs dystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Fuchs dystrophy?
What will be the growth rate of patients across the seven major markets?

Fuchs Dystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Fuchs dystrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Fuchs dystrophy market?
What are the key regulatory events related to the Fuchs dystrophy market?
What is the structure of clinical trial landscape by status related to the Fuchs dystrophy market?
What is the structure of clinical trial landscape by phase related to the Fuchs dystrophy market?
What is the structure of clinical trial landscape by route of administration related to the Fuchs dystrophy market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Fuchs Dystrophy - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Fuchs Dystrophy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Fuchs Dystrophy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Fuchs Dystrophy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Fuchs Dystrophy - Unmet Needs

10 Fuchs Dystrophy - Key Endpoints of Treatment

11 Fuchs Dystrophy - Marketed Products
11.1 List of Fuchs Dystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Fuchs Dystrophy - Pipeline Drugs
12.1 List of Fuchs Dystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 Netarsudil - Alcon
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ripasudil - Kowa Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 STN1010904 - ActualEyes/Santen Pharmaceutical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TTHX 1114 - Trefoil Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Fuchs Dystrophy - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Fuchs Dystrophy – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Fuchs Dystrophy - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Fuchs Dystrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Fuchs Dystrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Fuchs Dystrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Fuchs Dystrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Fuchs Dystrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Fuchs Dystrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Fuchs Dystrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Fuchs Dystrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Fuchs Dystrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Fuchs Dystrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Fuchs Dystrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Fuchs Dystrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Fuchs Dystrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Fuchs Dystrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Fuchs Dystrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Fuchs Dystrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Fuchs Dystrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Fuchs Dystrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Fuchs Dystrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Fuchs Dystrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Fuchs Dystrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Fuchs Dystrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Fuchs Dystrophy - Access and Reimbursement Overview

16 Fuchs Dystrophy - Recent Events and Inputs From Key Opinion Leaders

17 Fuchs Dystrophy Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Fuchs Dystrophy Market – Strategic Recommendations

19 Appendix